SLS vs IMVT vs ADMA vs NKTR vs CLDX

For growth investors, ADMA Biologics, Inc.

(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). ADMA Biologics, Inc. (ADMA) offers the better valuation at 14. 1x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate SELLAS Life Sciences Group, Inc. (SLS) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus SLS's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ADMA Biologics, Inc.

(ADMA) is the lower-risk stock at 1. 22β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 52% more volatile than ADMA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADMA Biologics, Inc.

(ADMA) is pulling ahead at 19. 6% versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). On earnings-per-share growth, the picture is similar: SELLAS Life Sciences Group, Inc. grew EPS 50. 0% year-over-year, compared to -59. 2% for Celldex Therapeutics, Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus -172. 5% for Celldex Therapeutics, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -191. 6% for CLDX. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ADMA: 165.

6% to $22. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ADMA Biologics, Inc.

(ADMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADMA: +39. 8%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SLS is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock; CLDX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.